Mabpharm Limited (HKG:2181)
Hong Kong · Delayed Price · Currency is HKD 0.4250
-0.0050 (-1.16%)
Nov 3, 2026, 4:08 PM HKT
Mabpharm Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,753 | 2,062 | 1,155 | 1,897 | 1,794 | 4,124 | |
Market Cap Growth | -18.27% | 78.57% | -39.13% | 5.75% | -56.50% | -4.76% |
Enterprise Value | 2,001 | 2,293 | 1,337 | 2,080 | 1,849 | 3,803 |
Last Close Price | 0.42 | 0.50 | 0.28 | 0.46 | 0.43 | 1.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 19.08 | 32.43 | - | - | - | - |
PS Ratio | 1.97 | 2.87 | 4.20 | 19.76 | 28.38 | 40.54 |
PB Ratio | 7.83 | 11.78 | 12.20 | 8.40 | 3.96 | 5.58 |
P/TBV Ratio | 7.83 | 11.78 | 12.20 | 8.40 | 3.96 | 5.58 |
P/FCF Ratio | 18.14 | 46.68 | - | 44.90 | - | - |
P/OCF Ratio | 14.77 | 22.94 | - | 30.00 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.25 | 3.19 | 4.87 | 21.66 | 29.24 | 37.38 |
EV/EBITDA Ratio | 18.12 | 34.76 | - | - | - | - |
EV/EBIT Ratio | 48.33 | 429.03 | - | - | - | - |
EV/FCF Ratio | 20.71 | 51.91 | - | 49.23 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.59 | 2.08 | 3.50 | 1.38 | 0.43 | 0.08 |
Debt / EBITDA Ratio | 3.23 | 5.06 | - | - | - | - |
Debt / FCF Ratio | 3.69 | 8.23 | - | 7.37 | - | - |
Net Debt / Equity Ratio | 1.11 | 1.38 | 2.50 | 0.53 | 0.31 | -0.06 |
Net Debt / EBITDA Ratio | 2.39 | 3.67 | -3.37 | -0.73 | -0.67 | 0.13 |
Net Debt / FCF Ratio | 2.57 | 5.48 | -7.35 | 2.85 | -0.67 | 0.10 |
Asset Turnover | 0.69 | 0.60 | 0.25 | 0.09 | 0.06 | 0.08 |
Inventory Turnover | 0.52 | 0.59 | 0.37 | 0.12 | 0.20 | 0.39 |
Quick Ratio | 0.49 | 0.50 | 0.62 | 0.69 | 0.47 | 0.53 |
Current Ratio | 0.84 | 0.81 | 1.17 | 1.08 | 1.07 | 1.05 |
Return on Equity (ROE) | 58.49% | 46.41% | -87.04% | -69.09% | -42.04% | -39.33% |
Return on Assets (ROA) | 2.00% | 0.28% | -7.29% | -12.93% | -15.56% | -18.03% |
Return on Capital Employed (ROCE) | 5.40% | 0.80% | -17.00% | -28.10% | -31.00% | -44.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.24% | 3.08% | -11.79% | -12.16% | -13.29% | -8.68% |
FCF Yield | 5.51% | 2.14% | -2.79% | 2.23% | -11.47% | -10.36% |